Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 24,384,000 | 22,090,000 | 22,465,000 | 23,002,000 | 24,708,000 |
| Cost of Goods | 4,921,000 | 4,936,000 | 4,318,000 | 4,126,000 | 4,646,000 |
| Gross Profit | 19,463,000 | 17,154,000 | 18,147,000 | 18,876,000 | 20,062,000 |
| Operating Expenses | 16,463,000 | 14,830,000 | 15,855,000 | 14,082,000 | 16,239,000 |
| Operating Income | 3,000,000 | 2,324,000 | 2,292,000 | 4,794,000 | 3,823,000 |
| Interest Expense | 1,402,000 | 1,366,000 | 1,360,000 | 1,367,000 | 1,039,000 |
| Other Income | -50,000 | 1,035,000 | 1,295,000 | 125,000 | 285,000 |
| Pre-tax Income | 1,548,000 | 1,993,000 | 2,227,000 | 3,552,000 | 3,069,000 |
| Income Tax | 321,000 | -57,000 | -641,000 | 146,000 | 243,000 |
| Net Income Continuous | 1,227,000 | 2,050,000 | 2,868,000 | 3,406,000 | 2,826,000 |
| Minority Interests | 108,000 | 105,000 | 133,000 | 93,000 | -1,000 |
| Net Income | $1,335,000 | $2,155,000 | $3,001,000 | $3,499,000 | $2,825,000 |
| EPS Basic Total Ops | 1.03 | 1.70 | 2.37 | 2.77 | 2.23 |
| EPS Basic Continuous Ops | 1.03 | 1.70 | 2.37 | 2.77 | 2.23 |
| EPS Diluted Total Ops | 1.03 | 1.70 | 2.37 | 2.76 | 2.23 |
| EPS Diluted Continuous Ops | 1.03 | 1.70 | 2.37 | 2.76 | 2.23 |
| EBITDA(a) | $6,712,000 | $7,112,000 | $6,623,000 | $7,276,000 | $6,960,000 |